Phaseline

Companies › Nuravax

Nuravax: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DUVAX
Vaccine targeting amyloid-beta and tau proteins
APP, MAPTPhase 1Alzheimer DiseaseApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07142278DUVAXPhase 1Alzheimer DiseaseNeurologyApr 2027

Targets

APP (1) MAPT (1)

Companies with the same targets

Roche Alnylam Pharmaceuticals Amyloid Solution Eli Lilly Eisai Acumen Pharmaceuticals JYAMS PET Research & Development HTA Eli Radiopharma Bristol-Myers Squibb

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.